Corvidia Therapeutics (Boston, Mass.) raised $26 million in a series A round and licensed cardiovascular mAb COR-001 from AstraZeneca plc (LSE:AZN; NYSE:AZN). Sofinnova Partners and Apple Tree Partners led the round. Corvidia said it would...

Ligand partnered with AstraZeneca's Omthera Pharmaceuticals Inc. subsidiary to develop products to treat dyslipidemia, including hypertriglyceridemia. The products will use Ligand's LTP technology to improve the lipid-lowering activity of omega-3 fatty acids. Ligand is eligible...

Pfizer Inc. continues to give signals that the grand plan is to break itself up, and the reality looks like it absolutely needs AstraZeneca plc 's assets to make it work. Pfizer already has internally...

FDA approved an NDA from AstraZeneca for Epanova as an adjunct to diet and exercise to treat severe hypertriglyceridemia, defined as triglyceride levels >=500 mg/dL. AZ expects to launch Epanova in the U.S. in 4Q14,...

FDA approved an NDA from AstraZeneca plc (LSE:AZN; NYSE:AZN) for Epanova as an adjunct to diet and exercise to treat severe hypertriglyceridemia, defined as triglyceride levels greater than or equal to 500 mg/dL. The pharma...

Novira Therapeutics Inc. , Radnor, Pa. Business: Infectious Hired: Christian Schade as CEO, formerly EVP and CFO of Omthera Pharmaceuticals Inc. , which AstraZeneca plc acquired WIR Staff...

AstraZeneca said FDA accepted for review an NDA for Epanova to treat severe hypertriglyceridemia, defined as triglyceride levels >=500 mg/dL. The PDUFA date is May 5, 2014. Epanova is an ultra-pure mixture of the free...

AstraZeneca plc (LSE:AZN; NYSE:AZN) said FDA accepted an NDA for Epanova to treat severe hypertriglyceridemia, defined as triglyceride levels greater than or equal to 500 mg/dL. The PDUFA date is May 5, 2014. Epanova is...

Even though this year's class of newly public biotechs is showing a stellar performance in the aftermarket, some IPO candidates have been forced to limp out or shelve their plans altogether. This suggests investors continue...

Seven years after its last major deal, FibroGen Inc. has now carved up worldwide rights to FG-4592 via its new deal with AstraZeneca plc . A key task for FibroGen is now to execute in China,...